Trial reportBMJ (Clinical research ed.)1994
Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure.
Trial report in BMJ (Clinical research ed.), 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 9 syntheses or guidelines pooled it, 222 citations in OpenAlex.
- Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease : A Systematic Review and Retrospective Individual Participant-Level Meta-analysis of Clinical Trials.Annals of internal medicine · 2024Pooled it
- The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).Hypertension research : official journal of the Japanese Society of Hypertension · 2019Guideline
- Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials.Hypertension research : official journal of the Japanese Society of Hypertension · 2019Pooled it
- Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis.Journal of the American Society of Nephrology : JASN · 2015Pooled it
- Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2014Pooled it
- Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis.PloS one · 2013Pooled it
- Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2011Pooled it
- Evidence-based practice guideline for the treatment of CKD.Clinical and experimental nephrology · 2009Guideline
- 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 1999Guideline
- Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention.Clinical journal of the American Society of Nephrology : CJASN · 2008Trial
- Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial.European journal of clinical pharmacology · 2005Trial
- Role of hypertension in progression of pediatric CKD.Pediatric nephrology (Berlin, Germany) · 2023Review
- Heart Failure in Patients with Chronic Kidney Disease.Journal of clinical medicine · 2023Review
- Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3-5: Are They Robust? A Fragility Index Analysis.Journal of clinical medicine · 2022Review
- Diagnosis 101: diabetic kidney disease.Clinical kidney journal · 2022Article
- Serum Protein Exposure Activates a Core Regulatory Program Driving Human Proximal Tubule Injury.Journal of the American Society of Nephrology : JASN · 2022Article
- Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.Nature reviews. Nephrology · 2022Review
- Review
- Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population.Scientific reports · 2019Article
- Longitudinal association of carotid endothelial shear stress with renal function decline in aging adults with normal renal function: A population-based cohort study.Scientific reports · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the ability of angiotensin converting enzyme inhibitors and beta blockers to slow the development of end stage renal failure in non-diabetic patients with chronic renal failure.
designOpen randomised multicentre trial with three year follow up.
settingOutpatient departments of six French hospitals. PATIENTS: 100 hypertensive patients with chronic renal failure (initial serum creatinine 200-400 mumol/l. 52 randomised to enalapril and 48 to beta blockers (conventional treatment).
interventionsEnalapril or beta blocker was combined with frusemide and, if necessary, a calcium blocker or centrally acting drug in patients whose diastolic pressure remained above 90 mm Hg.
results17 patients receiving conventional treatment and 10 receiving enalapril developed end stage renal failure. The cumulative renal survival rate was significantly better in the enalapril group than in the conventional group (P < 0.05). The slope of the reciprocal serum creatinine concentration was steeper in the conventionally treated patients (-6.89 x 10(-5)l/mumol/month) than in the enalapril group (-4.17 x 10(-5)l/mumol/month; P < 0.05). No difference in blood pressure was found between groups.
conclusionIn hypertensive patients with chronic renal failure enalapril slows progression towards end stage renal failure compared with beta blockers. This effect was probably not mediated through controlling blood pressure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.